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ABSTRACT 
Cancer cells frequently possess extra amplified centrosomes clustered into two poles whose 
pseudo-bipolar spindles exhibit reduced fidelity of chromosome segregation and promote genetic 
instability. Inhibition of centrosome clustering triggers multipolar spindle formation and mitotic 
catastrophe, offering an attractive therapeutic approach to selectively kill cells with amplified 
centrosomes. However, mechanisms of centrosome clustering remain poorly understood. Here, 
we identify a new pathway that acts through NIMA-related kinase 6 (Nek6) and Hsp72 to promote 
centrosome clustering. Nek6, as well as its upstream activators polo-like kinase 1 (Plk1) and 
Aurora-A, targeted Hsp72 to the poles of cells with amplified centrosomes. Unlike some 
centrosome de-clustering agents, blocking Hsp72 or Nek6 function did not induce formation of 
acentrosomal poles, meaning that multipolar spindles were observable only in cells with amplified 
centrosomes. Inhibition of Hsp72 in acute lymphoblastic leukaemia cells resulted in increased 
multipolar spindle frequency that correlated with centrosome amplification, while loss of Hsp72 or 
Nek6 function in non-cancer derived cells disturb neither spindle formation nor mitotic 
progression. Hence, the Nek6-Hsp72 module represents a novel actionable pathway for selective 
targeting of cancer cells with amplified centrosomes. 
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INTRODUCTION 
The mitotic spindle is bipolar in nature as it is organised around two poles, each possessing a 
single centrosome (1,2). However, the majority of cancer cells have H[WUD RU µamplified¶ 
centrosomes that would be expected to form multipolar spindles leading to mitotic catastrophe 
and cell death (3,4). Cancer cells solve this problem by either inactivating the extra centrosomes 
or clustering them into two poles to form a pseudo-bipolar spindle (5). The added time taken to 
organize such a spindle and presence of more than two centrosomes in early mitosis favours 
generation of merotelic microtubule-chromosome attachments that are poorly recognized by the 
spindle assembly checkpoint (SAC) (6,7). Hence, amplified centrosomes are not only tolerated 
but promote chromosome segregation errors, genome instability and cancer progression (8-10). 
 
Centrosomes act as the dominant microtubule organizing centres (MTOCs) in proliferating animal 
cells because they recruit the J-tubulin ring complex (J-TuRC) from which microtubules are 
nucleated (11,12). The J-TuRC is concentrated at centrosomes through binding to components of 
the pericentriolar material (PCM), a highly ordered matrix of coiled-coil proteins that surrounds 
and is scaffolded by a pair of centrioles (13). The centrioles are composed of nine triplets of 
highly stable microtubules organised into a polarised barrel that is duplicated once per cell cycle. 
Hence, cells in G1 have two centrioles, while cells in late G2 have four centrioles (14). These 
centrioles remain in close proximity during interphase due to proteinaceous ties that link them 
together (15). While each centriole is associated with its own PCM, the close juxtaposition of new 
centrioles with their parental centrioles in S/G2 mean that only two distinct PCM clouds are visible 
both before and after duplication. Hence, when scoring centrosome amplification, we use the 
criteria that cells should have more than two PCM foci and more than four centrioles. 
 
Experimental studies have revealed a number of microtubule-based processes that promote 
centrosome clustering, including motor protein activity, microtubule dynamics, and microtubule 
attachments to the centrosome, chromosomes and cell cortex (16-18). In addition, the extra time 
taken to organize a pseudo-bipolar spindle in cells with amplified centrosomes means that 
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clustering requires cells to have a robust spindle assembly checkpoint (SAC) that can delay 
anaphase onset until complete chromosome congression has been achieved (16,19). Targeting 
these different clustering processes could provide a selective approach to killing cancer cells with 
amplified centrosomes (20). However, the underlying mechanisms remain far from understood. 
 
Uncoupling of the centrosome duplication cycle from the cell cycle can result from altered activity 
of tumour suppressor genes and oncogenes and is a major route to centrosome amplification in 
cancer cells (21-23). This could arise from changes in gene expression of centrosome duplication 
regulators caused by deregulated signal transduction pathways. Alternatively, it could be due to 
reduced integrity of checkpoints, such as the SAC or DNA damage checkpoints, which disturb the 
timing of cell cycle progression and perturb coordination with the centrosome duplication cycle. 
Cancer cells also need to tolerate the presence of amplified centrosomes and destabilization of 
p53 through inactivation of the Hippo pathway may be a common mechanism in this regard (24). 
 
Oncogenesis is associated with proteotoxic stress that leads to induction of heat shock proteins 
(HSPs) required to maintain protein folding and homeostasis (25,26). As such HSPs represent 
cancer targets that are not necessarily restricted to tumours with particular driver mutations 
(27,28). Using RNAi depletion and chemical inhibitors, we recently found that Hsp72 is essential 
for mitotic spindle assembly in cancer cells, promoting stabilization of kinetochore-associated 
microtubules, (K)-fibres, through recruitment of the chTOG-TACC3 complex (29). This function of 
Hsp72 is dependent upon its phosphorylation by the Nek6 mitotic kinase. As Hsp72 and Nek6 are 
required for K-fibre stability and robust mitotic spindle assembly, we reasoned that they might 
also be required for clustering of amplified centrosomes. Here, we set out to test this hypothesis 
using fixed and time-lapse imaging of MDA-MB-231 (human breast carcinoma) and NIE-115 
(mouse neuroblastoma) cell lines that harbor amplified centrosomes and exhibit centrosome 
clustering activity (16,30,31). Our data reveal a new pathway of centrosome clustering and lead 
us to propose a therapeutic role for Hsp72 and/or Nek6 inhibitors as selective de-clustering 
agents in cancer cells with amplified centrosomes. 
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MATERIALS AND METHODS 
Cell culture, synchronisation, transfection and drug treatments 
All media were from Invitrogen and supplemented with 10% heat-inactivated foetal bovine serum 
(FBS), 100 IU/ml penicillin and 100 mg/ml streptomycin. MDA-MB-231, HeLa and HBL-100 cells 
were obtained from Cell Lines Service (CLS), while NIE-115 and RPE1-hTERT cells were 
obtained from ATCC. MDA-MB-231, NIE-115, HeLa and HBL-100 cells were cultured in 
'XOEHFFR¶VPRGLILHG(DJOH¶VPHGLXP'0(0, while RPE1-hTERT cells were grown in DMEM-
F12 with 0.25% sodium bicarbonate. Acute lymphoblastic leukemic (ALL) cells were obtained 
from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures 
(http://www.celllines.de) and grown in RPMI 1640 medium. PBLs are EBV transformed B-cells 
obtained from the Coriell Institute for Medical Research Biorepository (https://catalog.coriell.org). 
All cells were obtained within the last 10 years, stored in liquid nitrogen, and maintained in culture 
at 37qC in a 5% CO2 atmosphere for a maximum of 2 months. We relied on the provenance of the 
original collections for authenticity, while mycoplasma infection was avoided through bimonthly 
tests using an in-house PCR-based assay. RNAi-resistant wild-type and kinase-dead (KD, K75M) 
Flag-Nek6 constructs were generated using the QuikChange Site-Directed Mutagenesis Kit 
(Agilent Technologies) and transfections performed with Lipofectamine 2000 reagent (Life 
Technologies) according to manufacturers¶ instructions. Unless otherwise indicated, the following 
inhibitors were added to cells for 4 h: VER-155008 (Hsp70i, 10 µM; Tocris Bioscience); 
Griseofulvin (10 µM; Sigma); MLN8054 (Aurora-Ai; 500 nM; MedChem Express); BI-2536 (Plk1i; 
100 nM; MedChem Express). Control cells were treated with the same volume of DMSO. For 
microtubule regrowth, cells were incubated for 16 h with 50 ng/ml nocodazole (Sigma) followed 
by treatment with the 10 µM VER-155008 for 2 h. M-phase arrested cells were prepared by 
mitotic shake-off after 16 h nocodazole treatment. 
 
Fixed and live cell microscopy  
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Adherent cells were grown on acid-etched glass coverslips while suspension cells were seeded 
onto Superfrost Plus glass slides (Thermo). Cells were fixed with ice-cold methanol before being 
processed for immunofluorescence microscopy as previously described (29,32,33). For Hsp72 
staining, cells were incubated for 30 seconds in pre-extraction buffer (60 mM Pipes, 25 mM 
Hepes, pH7.4, 10 mM EGTA, 2 mM MgCl2, and 1% Triton X-100) prior to fixation. Primary 
antibodies were against D-tubulin (0.3 µg/ml; Sigma), J-tubulin (0.5 µg/ml; Sigma), centrin-2 (N-
17) (0.4 µg/ml; Santa Cruz Biotechnology), CEP135 (2 µg/ml; OriGene), pericentrin (2 µg/ml; 
Abcam), CenpA (2 µg/ml; Abcam), Hsp72 (0.8 µg/ml; C92F3A-5; Enzo Life Sciences), BubR1 (10 
µg/ml; Abcam) and phospho-Histone H3 (2 µg/ml; Abcam). DNA was stained with 0.8 µg/ml 
Hoechst 33258. Secondary antibodies were Alexa Fluor-488 and -594 goat anti-rabbit and goat 
anti-mouse IgGs (1 µg/ml; Invitrogen). Imaging was performed on a Leica TCS SP5 confocal 
microscope equipped with a Leica DMI 6000B inverted microscope using a 63x oil objective 
(numerical aperture, 1.4). Z-stacks comprising of 30-50 x 0.3 µm sections were acquired. Time-
lapse imaging was performed on a Leica TCS SP5 confocal microscope equipped with a Leica 
DMI 6000B inverted microscope using a 63x oil objective (numerical aperture, 1.4). Cells were 
cultured in glass-bottomed culture dishes (MatTek Corp.) and maintained at 37°C in an 
atmosphere supplemented with CO2 using a microscope stage temperature control system (Life 
Imaging Services). 50 nM SiR-tubulin (Spirochrome; SC002) was added 7 h before imaging when 
required. Z-stacks comprising 20 x 0.5 µm sections were acquired every 5 min for a minimum of 
16 h. Stacks were processed as maximum intensity projections using LAS-AF software (Leica) 
and movies prepared using ImageJ (v.1.51). To quantify spindle association of Hsp72, the mean 
pixel intensity over the whole spindle was measured using Volocity software and normalized to 
spindle microtubule intensity, while BubR1 association with kinetochores was quantified by 
measuring total pixel intensity over the chromatin using ImageJ software. 
 
RNAi 
Cells were seeded at 30-40% confluency in Opti-MEM Reduced Serum Medium and transfected 
using Oligofectamine (Life Technologies8.DFFRUGLQJ WRPDQXIDFWXUHU¶V LQVWUXFWLRQV. 100 nM 
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ON-TARGETplus siRNA duplexes were used against human Hsp72 (J-005168-06, J-005168-07), 
Nek6 (J-004166-06, J-004166-09) or Nek7 (J-003795-12, J-003795-14), or mouse Hsp72 (J-
054644-05, J-054644-07) obtained from Thermo Fisher Scientific (Lafayette, CO), or GAPDH 
(4390850), obtained from Life Technologies. siRNA duplexes were transfected. Cells were 
prepared for microscopy or Western blot analysis 72 h after transfection of siRNA duplexes. 
 
Cell lysis, SDS-PAGE and Western blotting 
Preparation of cell lysates, SDS-PAGE and Western blotting were performed as previously 
described (34). For Western blotting, primary antibodies were against Nek6 (1 µg/ml, Abcam), 
Nek7 (0.5 µg/ml, Abcam), Hsp72 (0.5 µg/ml, Enzo Life Sciences), Hsc70 (1 µg/ml, Santa Cruz) 
and GAPDH (1:1000, Cell Signaling). Secondary antibodies were goat or donkey anti-rabbit and 
anti-mouse horseradish peroxidase (HRP)-labelled IgGs (1:1000; Amersham, U.K.). 
 
Statistical analysis 
All quantitative data represent means and SD of at least three independent experiments. 
Statistical analyses were performed using a one-way ANOVA analysis; ****p<0.0001, ***p<0.001, 
**p<0.01, *p<0.05.  
 
RESULTS 
Hsp72 is required for centrosome clustering in cancer cells 
To examine the role of Hsp72 in centrosome clustering, we first assessed the frequency of 
centrosome amplification in a set of cancer and non-cancer-derived cell lines using antibodies 
against J-tubulin to count PCM foci and centrin-2 to score centrioles (Fig. 1A). Consistent with 
previous studies (16,30,31), 33.5% MDA-MB-231 human breast cancer and 96% NIE-115 mouse 
neuroblastoma cells were found to have >2 centrosomes in interphase, whereas only 8.3% HeLa 
human cervical cancer and 1% human RPE1 (retinal pigment epithelial cells immortalised with 
hTERT) had >2 centrosomes (Fig. 1B). To assess spindle polarity, cells were stained with 
antibodies against D-tubulin to detect microtubules and centrin-2 to score centrosomes. Scoring 
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only mitotic cells with >2 centrosomes (i.e. >4 centrin-2 stained centrioles), 82% MDA-MB-231 
and 76% NIE-115 cells formed pseudo-bipolar spindles with the amplified centrosomes clustered 
at two poles (Fig. 1C, D). 
 
Spindle organization was then assessed in MDA-MB-231 and NIE-115 cells treated with 
increasing doses (5-20 µM) VER-155008, a chemical inhibitor of Hsp70 (35). This revealed a 
dose-dependent increase in the frequency of cells with amplified centrosomes that had multipolar 
spindles following treatment with the Hsp70i (Fig. 1E-G). As VER-155008 inhibits all members of 
the Hsp70 family, we confirmed the specific role of the inducible Hsp72 isoform in centrosome 
clustering using two independent siRNA oligonucleotides to deplete the protein from MDA-MB-
231 and NIE-115 cells. Both siRNAs caused a significant increase in multipolar spindles in cells 
with amplified centrosomes as compared to mock-depleted cells, while Western blotting 
confirmed that siRNAs depleted Hsp72 but not the constitutive Hsc70 in each cell line (Fig. 1H, I, 
and Supp. Fig. S1A, B). Hence, we conclude that Hsp72 is essential for centrosome clustering in 
cancer cells with amplified centrosomes. 
 
Hsp72 promotes resolution of multipolar to bipolar spindles 
To analyse the role of Hsp72 in centrosome clustering, we took advantage of a far-red fluorescent 
probe, SiR-tubulin, that can stain microtubules in live cells (33,36). Addition of SiR-tubulin 
revealed the initial assembly of multipolar spindles in NIE-115 cells following mitotic entry (Fig. 
2A, B). However, following a mean time of 78 mins in a multipolar state, these spindles 
subsequently resolved into a bipolar state before cells progressed into anaphase and completed 
division (Fig. 2C). In the presence of the Hsp70i, there was little difference from untreated cells in 
the length of prophase, measured from when a robust microtubule array formed to when nuclear 
envelope breakdown occurred. However, after assembling a multipolar spindle, this state was 
maintained for extended time in the presence of the Hsp70i with only ~50% cells resolving the 
spindle into a pseudo-bipolar state within the time-frame of the experiment (700 mins); for those 
cells in which the spindle did resolve into a pseudo-bipolar state they spent a mean of 480 mins in 
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metaphase (Fig. 2A-C). Analysis of cells depleted of Hsp72 using the same approach gave 
similar results confirming the specific role of Hsp72 in this process (Fig. 2C). Likewise, inhibition 
of Hsp70 or depletion of Hsp72 in MDA-MB-231 cells led to multipolarity with a mean time of 
>500 mins in metaphase (Fig. 2D). These data reveal that in these cell types the multiple MTOCs 
generated by the presence of amplified centrosomes are resolved to a pseudo-bipolar state as a 
result of centrosome clustering rather than centrosome inactivation. Moreover, they confirm that 
loss of Hsp72 function prevents this from occurring thereby stopping cells from satisfying the SAC 
and proceeding into late mitosis. 
 
Nek6 kinase activity is required for centrosome clustering in cancer cells 
Our previous studies revealed that Hsp72 promotes spindle assembly in mitotic cells downstream 
of the protein kinase Nek6 (29). To determine whether a similar pathway is involved in 
centrosome clustering, we depleted MDA-MB-231 cells of either Nek6 or the closely related Nek7 
kinase. Although Nek6 and Nek7 have almost identical catalytic sites, they have distinct substrate 
specificities that result from their distinct N-termini (37), and Nek6 but not Nek7 interacts with 
Hsp72 (29). Each kinase was independently depleted with two different oligonucleotides and 
depletion confirmed by Western blot (Supp. Fig. S1C). Whereas removal of Nek7 had no effect 
on centrosome clustering, depletion of Nek6 led to a substantial increase in the frequency of cells 
with amplified centrosomes that had multipolar spindles indicative of a failure in centrosome 
clustering (Fig. 3A, B). Strikingly, wild-type but not kinase-inactive Nek6 was capable of rescuing 
centrosome clustering in cells from which Nek6 had been depleted demonstrating the 
requirement for Nek6 kinase activity in this process (Fig. 3B). 
 
In MDA-MB-231 cells that had been detergent-extracted prior to fixation to remove soluble 
protein, Hsp72 was observed at spindle poles consistent with previous observations in other cell 
types (29,38-40). However, this localization was lost upon Nek6, but not Nek7, depletion despite 
no change in overall expression of Hsp72 (Fig. 3C, D; Supp. Fig. S1D). Further evidence that 
Nek6 and Hsp72 cooperate in centrosome clustering came from demonstrating that chemical 
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inhibition of either Aurora-A or Plk1, both of which act upstream of Nek6 and induce monopolar 
spindle formation (41,42), prevent localization of Hsp72 to spindle poles without disturbing its 
expression (Fig. 3C, D, and Supp. Fig. S1E, F). Similar loss of Hsp72 localization upon Aurora-A 
or Plk1 inhibition was observed in NIE-115 cells (Fig. 3E). Thus, we propose that a pathway 
acting through the Aurora-A, Plk1 and Nek6 kinases targets Hsp72 to the spindle apparatus. 
 
Mitotic cells lacking Hsp72 or Nek6 activity do not form acentrosomal spindle poles 
As a potential strategy for targeting cancer cells with amplified centrosomes, we compared the 
phenotypes generated upon loss of Hsp72 or Nek6 function, with the action of a well 
characterised centrosome declustering agent, griseofulvin (43). As expected, griseofulvin induced 
generation of multipolar spindles in MDA-MB-231 cells with amplified centrosomes (Fig. 4A, B). 
However, it led to an even higher frequency of multipolar spindles in HeLa cells, which do not 
exhibit substantial centrosome amplification (Fig. 4A, B). Analysis of these cells with centriole 
markers revealed that griseofulvin induces formation of microtubule asters in mitotic cells that 
ODFNFHQWULROHVVRFDOOHGµDFHQWURVRPDO¶SROHV)LJ&' In contrast, MDA-MB-231 cells treated 
with the Hsp70i, or depleted of Hsp72 or Nek6, did not form acentrosomal poles, with all poles in 
the multipolar spindles containing centrioles (Fig. 4C, D). 
 
Acentrosomal poles also arise in mitotic cells following nocodazole-induced microtubule 
depolymerisation and subsequent nocodazole washout. However, these quickly resolve to form a 
bipolar spindle. To observe, how cells with acentrosomal poles respond in the absence of Hsp70 
activity, NIE-115, MDA-MB-231 and HeLa cells were treated for 16 h with nocodazole and then 
released into nocodazole-free media in the presence or absence of the Hsp70i (Supp. Fig. S2A). 
In the absence of Hsp70i, NIE-115 cells initially had multiple microtubule asters but these largely 
resolved within 60 mins to two asters (Fig. 4E, and Supp. Fig. S2B). However, in the presence of 
the Hsp70i, these multiple asters did not resolve and the percentage of cells with >2 asters 
remained relatively constant. With the MDA-MB-231 cells, there was a partial resolution in the 
presence of the Hsp70i consistent with the lower frequency (~35%) of cells with amplified 
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centrosomes (Fig. 4F). In contrast, in HeLa cells that do not have amplified centrosomes, the 
multiple asters resolved to form a bipolar spindle at a similar rate in the presence or absence of 
Hsp70i (Fig. 4G, and Supp. Fig. S2C). Hence, Hsp70 is required to cluster microtubule asters 
organised by bona fide centrosomes, but not to cluster microtubule asters generated by 
acentrosomal poles. 
 
Spindle polarity correlates with centrosome number in ALL cells 
To address the role of inhibiting Hsp70 in a particular cancer setting, we opted to assess a panel 
of acute lymphoblastic leukaemia (ALL) cell lines, on the basis that childhood ALL is a cancer 
typically treated with the microtubule poison, vincristine (44). This treatment is effective but 
associated with significant toxicity and risks of secondary cancers due to the lack of selectivity for 
cancer cells. For this analysis, ten ALL cell lines were analysed as well as two non-cancer 
derived peripheral B-lymphocyte (PBL) cell lines. Despite being non-adherent cell lines with high 
nuclear-to-cytoplasmic ratios that make them sub-optimal for imaging, we optimised techniques to 
assess centrosome number using antibodies against Cep135 to stain centrioles and either J-
tubulin or pericentrin to stain the PCM (33). While PBLs had a very low frequency (<5%) of cells 
with amplified centrosomes, the majority of ALL cell lines exhibited centrosome amplification 
within a range of 10-30% cells (Fig. 5A, B). Treatment with the Hsp70i revealed a dose-
dependent increase in the frequency of multipolar spindles that correlated strongly with extent of 
centrosome amplification (Fig. 5C, D). In contrast, griseofulvin induced multipolar spindle 
formation to the same extent in all cells, including the PBLs, due to generation of acentrosomal 
poles (Fig. 5E, F). Western blotting revealed increased expression of Hsp72 in most, but not all 
ALL cell lines compared to PBLs, while Nek6 was present at similar levels in ALL and PBL cell 
lines (Supp. Fig. S1F). Hence, inhibiting the Nek6-Hsp72 pathway represents a potential route to 
selective targeting of ALL cells with amplified centrosomes. 
 
Hsp72 and Nek6 are not required for mitotic progression in non-cancer derived cells 
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Targeting the Nek6-Hsp72 pathway for cancer therapy would only improve selectivity if these 
proteins are not required for proliferation of normal cells. In fact, we have previously shown that 
this pathway is required for robust spindle assembly in HeLa cells arguing that their role extends 
beyond centrosome clustering in cancer cells (29). Importantly, we found that while Hsp70 
inhibition blocked chromosome congression in both HeLa and MDA-MB-231 cells, treatment with 
the Hsp70i did not lead to chromosome congression defects in the non-cancer derived RPE1 and 
HBL-100 cell lines (Fig. 6A, B). Encouragingly, we also found that depletion of Hsp72 or Nek6 led 
to a similar level of chromosome congression defects in HeLa and MDA-MB-231 cells, but did not 
interfere with chromosome congression in RPE1 and HBL-100 cells (Fig. 6C). Measurement of 
mitotic index by analysis of condensed chromatin and staining for the phospho-histone H3 
(pHH3) marker confirmed that Hsp70 inhibition caused a significant delay in mitotic progression in 
HeLa and MDA-MB-231 cells, but not in RPE1 and HBL-100 cells (Fig. 6D, and Supp. Fig. S3A). 
Time-lapse imaging of RPE1 cells incubated with the SiR-tubulin probe also revealed no change 
in mitotic duration or spindle shape upon treatment with the Hsp70i or depletion of Hsp72 (Fig. 
6E, and Supp. Fig. S3B, C). As expected, Western blotting revealed that the non-cancer derived 
cells lines, RPE1 and HBL-100, exhibited lower expression levels of the inducible Hsp72 protein 
than the cancer lines, MDA-MB-231 and HeLa (Supp. Fig. S3D, E). Finally, we showed that while 
Hsp70 inhibition can perturb K-fibre assembly, it did not prevent SAC activation as determined by 
recruitment of BubR1 in nocodazole-treated MDA-MB-231 cells (Fig. 6F, G). Thus, we propose 
that the Nek6-Hsp72 pathway is required for spindle organization and centrosome clustering, but 
not SAC activity, in cancer cells but not essential for mitotic progression in normal cells. This 
pathway therefore represents an attractive target for development of novel anti-cancer therapies. 
 
DISCUSSION 
Centrosome amplification is frequently observed in cancer cells and associated with poor 
prognosis (3). To allow cell survival, the extra centrosomes are clustered to enable formation of a 
pseudo-bipolar spindle that can support chromosome segregation. Centrosome clustering has 
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therefore emerged as a potentially exciting avenue for cancer drug discovery based on the 
principle of selective disruption of mitosis in cells with amplified centrosomes (18,45). 
 
Here, we demonstrate that the Nek6-Hsp72 axis, together with the upstream Aurora-A, Plk1 and 
presumably Nek9 kinases, represents a novel pathway for regulating centrosome clustering (Fig. 
6H). Nek6-phosphorylated Hsp72 regulates the spindle association of the chTOG-TACC3 
complex (29). This complex was previously implicated in centrosome clustering through its 
regulation by integrin-linked kinase (ILK), inhibition of which prevents centrosome clustering (30). 
Spindle association of chTOG-TACC3 also requires clathrin, a known binding partner of Hsp70 
chaperones (46). Our working hypothesis is that phosphorylation of Hsp72 by Nek6 modulates 
the interaction of clathrin with TACC3 and/or microtubules to favour spindle association of the 
complex, thereby promoting K-fibre stability (47). However, there could equally be other Nek6 
and/or Hsp72 targets associated with centrosome and/or kinetochore attachments (including 
motors, such as Eg5, HSET or dynein) that promote tension in K-fibres. These mechanisms are 
under investigation. 
 
A major challenge is to identify mechanisms that play an essential role in centrosome clustering 
but which can be safely inhibited in normal cells. Multipolar spindles can result from perturbation 
of many different spindle associated proteins, but there are few examples so far of proteins that 
show selective effects in cancer cells with amplified centrosomes and that are amenable to 
inhibition with a drug-like molecule. One example is HSET/KIFC1, a minus end-directed 
microtubule motor of the kinesin-14 family (48,49). Multipolar spindle formation is induced upon 
treatment of cancer cells harbouring amplified centrosomes with either of two distinct HSET 
inhibitors: AZ82, which blocks the ATP binding pocket, or CW069, which binds to an allosteric 
site. However, cells with a normal complement of centrosomes are still affected by these 
inhibitors and, whilst only transient, multipolarity can occur in these cells that may either trigger 
cell death or induce genetic instability. 
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One concern with certain compounds developed as centrosome de-clustering agents, such as 
griseofulvin and its derivatives (43), is that they induce formation of acentrosomal spindle poles, 
i.e. poles that do not contain or arise from bona fide centrosomes. Similar acentrosomal poles are 
formed upon treatment of cells with taxol-based drugs, and this could be a common feature of de-
clustering agents that work by disturbing microtubule dynamics or motors that crosslink 
microtubules. The fact that we never saw acentrosomal poles upon loss of Hsp72 or Nek6 
function argues that this pathway acts through some other mechanism. The fluorescent tubulin 
probe allowed us to directly monitor microtubule organization in live mitotic cells and revealed that 
it is resolution of a multipolar to bipolar state that is inhibited in cells with amplified centrosomes. 
This was supported by nocodazole washout experiments that showed acentrosomal poles formed 
in HeLa cells with normal centrosome numbers clustered efficiently in the presence of the Hsp70 
inhibitor. These data rather argue for a specific role for this pathway at points of microtubule 
attachment to centrosomes, kinetochores or the cell cortex and is reassuring from a therapeutic 
perspective as it demonstrates selectivity towards cells with amplified centrosomes. 
 
There is further potential patient-benefit in targeting the Nek6-Hsp72 pathway as both 
components are overexpressed in cancer versus normal cells (50,51). Moreover, normal cells 
may have a reduced requirement for this pathway compared to cancer cells with no evidence of 
mitotic delays or segregation errors in either immortalised RPE1 or HBL100 cells. From a 
practical perspective though there are limitations in directly targeting Hsp72. First, different Hsp70 
family members are highly similar in active site structure and it will be difficult to develop catalytic 
inhibitors tKDW GRQ¶W DOVR WDUJHW RWKHU IDPLO\ PHPEHUV with essential roles in normal cell 
homeostasis. For this reason, simply measuring cell survival in response to Hsp70 inhibition may 
well not reveal a direct correlation with centrosome number. Second, Hsp70 is proving to be a 
challenging drug target due to its high affinity for nucleotide. In contrast, having demonstrated a 
requirement for Nek6 activity for centrosome clustering, this kinase may well make a more 
attractive target than Hsp72. Indeed, while there is significant sequence similarity within the 
catalytic sites with other NEKs, particularly Nek7, we are developing approaches to generate 
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selective inhibitors that target not only the catalytic site but also the more divergent allosteric sites 
required for activation (52).  
 
At the same time as developing Nek6 inhibitors, we need to identify groups of patients who might 
benefit from centrosome de-clustering agents. Although inhibiting this pathway causes problems 
in mitotic progression in cancer cells even without centrosome amplification, we argue that extra 
centrosomes would sensitise cancer cells to mitotic catastrophe in a physiological setting and are 
therefore a valuable and relatively easy to measure biomarker, especially in haematological 
malignancies (4). Genetic changes known to cause centrosome amplification, such as Aurora-A 
overexpression or BRCA1 loss, may also represent useful biomarkers for selecting clinical trial 
cohorts (8). Here, we show that a subset of ALL cell lines harbour amplified centrosomes and 
most of these have the capacity to cluster the extra centrosomes to avoid generating multipolar 
spindles. Furthermore, treatment with an Hsp70 inhibitor led to loss of clustering with the 
frequency of multipolar spindles closely reflecting the extent of centrosome amplification. ALL 
cells represent a good model for a disease that has traditionally been treated with anti-mitotic 
chemotherapies and, DOWKRXJKZHKDYHQ¶WH[SORUHGFHOOsurvival for the reasons given above, it 
could be that centrosome number acts as a biomarker for stratification. High levels of centrosome 
amplification have previously been observed in other haematological malignancies, including 
DLBCL, MCL and CML (4). Future work will be important to identify genetic signatures that dictate 
the response of blood cancers to centrosome de-clustering strategies and enable the clinical 
development of new targeted agents. 
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FIGURE LEGENDS 
 
Figure 1. Loss of Hsp72 function blocks centrosome clustering 
A. MDA-MB-231, HeLa, NIE-115 and RPE1 cells were stained for centrin-2 JUHHQ Ȗ-tubulin 
(red) and DNA (blue). B. Histogram shows the percentage of interphase cells from A exhibiting 
centrosome amplification (CA, >2 centrosomes). C. MDA-MB-231 and NIE-115 cells were stained 
for centrin-2 (green), Į-tubulin (red) and DNA (blue). D. Histogram shows the percentage of 
metaphase cells from C with amplified centrosomes with bipolar or multipolar spindles. E. MDA-
MB-231 and NIE-115 cells were either untreated (control) or treated with the Hsp70i at the dose 
indicated before being fixed and stained as in C. F, G. Histograms show the percentage of cells 
with amplified centrosomes shown in E that had multipolar spindles. H. I. Histograms show the 
percentage of cells with amplified centrosomes that had multipolar spindles following mock or 
Hsp72 depletion using two distinct siRNAs. In A, C and E, scale barVȝPPDJQLILHGYLHZVRI
centrosomes are shown. Data in B, D, F, G, H and I are n=4, >400 cells.  
 
Figure 2. Resolution of a multipolar to bipolar state is blocked by Hsp70 inhibition 
A. NIE-115 cells were incubated with SiR-tubulin prior to time-lapse imaging in the presence or 
absence of Hsp70i. Still images are shown of SiR-tubulin alone (top rows) and merged with 
brightfield (BF; bottom rows) at the times indicated. Arrowheads indicate spindle poles; arrows 
indicate daughter cells following division. Scale bars, 20 µm. B. Time-lapse imaging of NIE-115 
cells in the absence (control) or presence of Hsp70i was used to determine the time spent in each 
stage of mitosis as indicated; each bar is representative of a single cell. C, D. Histograms show 
the time spent with a multipolar spindle in control, Hsp70i treated or siHsp72-depleted NIE-115 
(C) or MDA-MB-231 (D) cells; n=3; 15 cells. 
 
Figure 3. Nek6 kinase activity is required for centrosome clustering 
A. MDA-MB-231 cells were mock-depleted or depleted with siRNAs against Nek6 or Nek7 before 
being stained for centrin-2 (grHHQ DQG Į-tubulin (red). Merge images include DNA (blue). B. 
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Histogram shows the percentage of mitotic cells with amplified centrosomes that had multipolar 
spindles. Cells were treated as in A, as well as transfected with wild-type or kinase-dead (KD) 
Flag-Nek6 following Nek6 depletion. The different Nek6 and Nek7 siRNAs used are indicated. C. 
MDA-MB-231 cells that were mock-depleted, depleted of Nek6 or Nek7, or treated with Aurora-A 
or PLK1 inhibitors were stained for Hsp72 (green), D-tubulin (red) and DNA (blue in merge). D. 
Histogram shows the spindle intensity of Hsp72 relative to microtubules in mitotic MDA-MB-231 
cells treated as indicated. Data in B and D, n=3, >300 cells. E. NIE-115 cells that were mock-
treated or treated with Aurora-A or PLK1 inhibitors were stained for Hsp72 (green), D-tubulin (red) 
and DNA (blue in merge).  Scale bars in A, C and EȝP 
 
Figure 4. Loss of Hsp72 or Nek6 function does not induce acentrosomal pole formation 
A. MDA-MB-231 and HeLa cells were either untreated (control) or treated with 10 µM griseofulvin 
before being stained for centrin-2 (green). Merge panels include Į-tubulin (red) and DNA (blue). 
B. Histogram shows the percentage of cells with amplified centrosomes that had multipolar 
spindles following the treatments shown. C. MDA-MB-231 cells that were depleted with siRNAs 
against Hsp72 or Nek6 as indicated, or treated with 10 µM griseofulvin, were stained as in A. D. 
Histogram shows the percentage of mitotic MDA-MB-231 cells from C, as well as HeLa cells 
treated with 10 µM griseofulvin, with acentrosomal spindle poles. E-G. The percentage of mitotic 
NIE-115 (E), MDA-MB-231 (F) and HeLa (G) cells with >2 microtubule asters upon release into 
nocodazole-free media in the absence (control, black line) or presence (red line) of Hsp70i is 
indicated. Enlarged views of spindle poles are shown in A and C; scale barsȝP Data in B and 
D-G, n=3, >200 cells. 
 
Figure 5. Hsp70 inhibition blocks centrosome clustering in ALL cells 
A. Peripheral blood lymphocyte (PBL) or acute lymphoblastic leukaemia (ALL) cell lines were 
stained for CEP135, Ȗ-tubulin and DNA. Enlargements of centrosomes are shown. B. Histogram 
shows percentage of interphase cells with amplified centrosomes. C. Cells were treated with 10 
µM Hsp70i for 4 h and stained for CEP135, D-tubulin and DNA. D. Histogram shows the 
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percentage of mitotic cells with multipolar spindles following Hsp70i treatment at the dose 
indicated (µM). E. Cells were treated with 10 µM griseofulvin and VWDLQHGIRUSHULFHQWULQĮ-tubulin 
and DNA. F. Histogram shows percentage of mitotic cells with multipolar spindles following 
griseofulvin treatment at the dose indicated (µM). Scale bars in A, C and E, ȝP Data in B, D 
and F, n=4, >400 cells. 
 
Figure 6. Hsp70 inhibition does not interfere with mitosis in diploid cells 
A. Cells that were untreated (control, MDA-MB-231) or treated with 10 µM Hsp70i for 4 h were 
VWDLQHG ZLWK &HQS$ JUHHQ DQG Į-tubulin (red). Misaligned chromosomes are indicated with 
arrowheads. B. Histogram shows the percentage of mitotic cells with misaligned chromosomes 
upon treatment with Hsp70i at the dose indicated. C. Histogram shows the percentage of mitotic 
cells with misaligned chromosomes following mock depletion or depletion of Hsp72 or Nek6 as 
indicated. D. Histogram shows the mitotic index upon Hsp70i treatment at the dose indicated. 
Data in B-D, n=4, >400 cells. E. Time-lapse imaging of RPE1 cells was performed in the 
presence of SiR-tubulin following no treatment, 10 µM Hsp70i or Hsp72 depletion and the 
duration of mitosis recorded for 20 cells in each condition; each dot represents one cell. F. MDA-
MB-231 cells were treated with nocodazole for 16 hours before further addition of DMSO or 
Hsp70i for 4 hours. Cells were stained with BubR1 (green). Merge images in A and F include 
DNA (blue); scale barsȝP G. Histogram of BubR1 intensity at kinetochores relative to CenpA. 
H. The schematic model shows the Nek6-Hsp72 pathway (including upstream activators) 
promoting centrosome (red dots) clustering and pseudo-bipolar spindle formation, with 
declustering and multipolarity resulting from Hsp70 inhibition, or depletion of Hsp72 or Nek6. 
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